Synact Pharma

SynAct Pharma is a clinical stage biotechnology company specializing in resolving inflammation by leveraging melanocortin biology. The company focuses on selective activation of the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms. This approach aims to resolve excessive or chronic inflammation safely without compromising the immune system's ability to respond to new infections or injuries. SynAct Pharma primarily serves the healthcare and pharmaceutical sectors, targeting conditions related to chronic inflammation. Operating in the biotechnology market, the company follows a business model centered around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved treatments.

Keywords: inflammation, melanocortin, biotechnology, clinical stage, immune system, anti-inflammatory, healthcare, pharmaceutical, chronic conditions, R&D.